Aquestive Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
AQST$3.52-0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows for the Years Ended
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities: | ||
| Net loss | $(7,870) | $(54,410) |
| Adjustments to reconcile net loss to net cash used for operating activities: | ||
| Depreciation, amortization, and impairment | 1,345 | 2,387 |
| Share-based compensation | 2,689 | 4,381 |
| Amortization of debt issuance costs and discounts | 1,972 | 215 |
| Interest expense related to the sale of future revenue | — | 5,683 |
| Loss on the extinguishment of debt | 1,029 | — |
| Other, net | (204) | (52) |
| Changes in operating assets and liabilities: | ||
| Trade receivables and other receivables, net | (3,073) | 7,352 |
| Inventories | (989) | (1,743) |
| Prepaid expenses and other assets | 1,290 | 1,399 |
| Accounts payable | (1,020) | 1,633 |
| Accrued expenses and other liabilities | (2,515) | (2,382) |
| Deferred revenue | 966 | 25,043 |
| Notes Payable | — | 675 |
| Net cash used for operating activities | (6,380) | (9,819) |
| Cash flows from investing activities: | ||
| Capital expenditures | (995) | (1,024) |
| Additions to intangible assets | — | (1,500) |
| Net cash used for investing activities | (995) | (2,524) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock under public equity offering, net | 8,912 | 3,907 |
| Proceeds from common stock and warrants issued under private equity offering, net | — | 9,679 |
| Proceeds from exercise of warrants, net | 8,307 | — |
| Proceeds from shares issued under employee stock purchase plan | 39 | 34 |
| Proceeds from exercise of stock options | 1 | — |
| Proceeds from issuance of debt | 31,144 | — |
| Proceeds from issuance of Royalty Rights Agreements | 13,856 | — |
| Debt repayments | (51,529) | — |
| Payments for financing costs | (4,643) | — |
| Premium paid to retire debt | (2,102) | (2,025) |
| Payments for taxes on share-based compensation | (11) | (3) |
| Net cash provided by financing activities | 3,974 | 11,592 |
| Net decrease in cash and cash equivalents | (3,401) | (751) |
| Cash and cash equivalents: | ||
| Beginning of period | 27,273 | 28,024 |
| End of period | $23,872 | $27,273 |
| Supplemental disclosures of cash flow information: | ||
| Cash payments for interest | $4,602 | $6,436 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.